About the study

This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients, and to Evaluate the Safety and Preliminary Efficacy in Advanced esophagus canver and Squamous cell carcinoma of the esophageal junction patients

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

1. main inclusion:
2. Evidence of a personally signed informed consent document;
3. Male and/or female subjects above the ages of 18 years;
4. Locally advanced or metastatic solid tumor patients who have failed or relapsed on current standard of care for Phase 1a;
5. Subject may provide Tumor tissue section(at least 8 pieces) if they agree;
6. ECOG performance score 0-1;
7. Life expectancy ≥ 12 weeks;
8. At least 1 measurable target lesion on the baseline scan as per RECIST 1.1

Exclusion criteria

1. main criteria:
2. prior received anti-tumor treatment, including anticancer drugs for the treatment within 28 days of first dose of study treatment;
3. Prior or concomitant other malignant tumor;

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.